Benralizumab (Fasenra®)

Benralizumab (Fasenra) is covered as add‑on maintenance therapy for patients ≥12 years with severe eosinophilic asthma who have blood eosinophils ≥150 cells/µL, have failed/tried ≥3 months of specified controller regimens (ICS + anti‑IL‑5 or ICS + another controller, or an ICS/LABA inhaler), and have uncontrolled disease by ≥1 criterion (≥2 steroid‑treated exacerbations or ≥1 hospitalization/ED visit in the prior year, FEV1 <80% predicted, FEV1/FVC <0.80, or worsening with oral steroid taper), prescribed by or in consultation with an allergist/immunologist/pulmonologist. Initial approval is for 6 months (renewable for 12 months) and renewals require ≥6 months of Fasenra use, continued ICS or ICS‑combination therapy, documentation of clinical response (fewer exacerbations/symptoms/hospitalizations or reduced oral steroid use), and dosing consistent with 30 mg SC q4 weeks ×3 then q8 weeks.

"Fasenra is indicated for the add-on maintenance treatment of pateints with severe asthma aged 12 years and older with an eosinophilic phenotype."